Pancreatitis risk rises with popular weight loss drugs: study
Semaglutide and liraglutide use associated with a higher risk of gastrointestinal disorders versus bupropion–naltrexone, say Canadian researchers.
Patients using GLP-1 receptor agonists for weight loss are nine times more likely to develop pancreatitis than those taking bupropion–naltrexone, Canadian researchers say.
Use of liraglutide (Saxenda) and semaglutide (Ozempic and Wegovy) were also associated with a near fourfold increased risk of bowel obstruction and gastroparesis compared with the older fixed-dose combination treatment.
